Thyme Care has raised $125.0M in a Series E round, a significant infusion for the company as it works to reshape how cancer care is coordinated and paid for.
The startup operates at the intersection of patients, providers, and health plans, using dedicated care teams and technology to keep everyone aligned on a shared model of care. Its pitch is straightforward: by integrating into existing clinical workflows and closing gaps between visits, it can drive better outcomes while also lowering costs-a dual promise that has clearly resonated with investors willing to back it at this scale.
